AstraZeneca forges new biomarker deal; African-Americans may have unique Alzheimer's gene variation;

> AstraZeneca ($AZN) forged a new biomarker discovery deal with U.K.-based Oxford Cancer Biomarkers, focused on predicting who will respond best to a new cancer drug under development. More

> African-Americans appear to have a minor difference in their genes, compared to Caucasians, that can help identify the risk of Alzheimer's. Item

> Quest Diagnostics ($DGX) will use metabolomics biomarkers recently discovered by Matrix-Bio to develop a test that detects the recurrence of breast cancer. Item

> Emory University scientists spotted a new cerebrospinal fluid biomarker that can help distinguish between two major subtypes of frontotemporal lobar degeneration in living patients. Story (reg. req.)

> IVD tests that use molecular biomarkers seem to have increasingly long review periods compared to IVDs overall, Amplion Research has concluded. Item

Suggested Articles

The former Fierce 15 winner’s SuperMap program was cleared to guide electrophysiologists in the treatment of stable and transient arrhythmias.

Insulet announced new agreements with Abbott and Dexcom to connect their continuous glucose monitors with its upcoming tubeless, digital insulin pump,

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.